BNP Paribas Asset Management
BIO icon

BNP Paribas Asset Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

BNP Paribas Asset Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$81.3K Sell
277
-44
-14% -$12.5K ﹤0.01% 1611
2026
Q1 		$89.5K Buy
321
+67
+26% +$19.3K ﹤0.01% 1541
2025
Q4 		$77K Buy
254
+73
+40% +$22.8K ﹤0.01% 1540
2025
Q3 		$51K Sell
181
-5
-3% -$1.36K ﹤0.01% 1049
2025
Q2 		$45K Buy
+186
New +$44K ﹤0.01% 1176
2025
Q1 		– Sell
-722
Closed -$237K – 872
2024
Q4 		$237K Sell
722
-81
-10% -$27.5K ﹤0.01% 881
2024
Q3 		$269K Sell
803
-933
-54% -$296K ﹤0.01% 859
2024
Q2 		$474K Buy
1,736
+795
+84% +$231K ﹤0.01% 881
2024
Q1 		$325K Buy
941
+124
+15% +$40.8K ﹤0.01% 840
2023
Q4 		$264K Buy
817
+101
+14% +$31.7K ﹤0.01% 819
2023
Q3 		$257K Buy
+716
New +$276K ﹤0.01% 823
2023
Q2 		– Sell
-440
Closed -$211K – 858
2023
Q1 		$211K Sell
440
-2,186
-83% -$1.02M ﹤0.01% 864
2022
Q4 		$1.1M Buy
2,626
+172
+7% +$69.4K ﹤0.01% 764
2022
Q3 		$1.02M Buy
2,454
+268
+12% +$134K ﹤0.01% 754
2022
Q2 		$1.08M Sell
2,186
-449
-17% -$234K ﹤0.01% 771
2022
Q1 		$1.48M Buy
+2,635
New +$1.59M 0.01% 691
2016
Q4 		– Sell
-3,806
Closed -$623K – 985
2016
Q3 		$623K Hold
3,806
– – 0.01% 912
2016
Q2 		$544K Hold
3,806
– – ﹤0.01% 949
2016
Q1 		$520K Hold
3,806
– – ﹤0.01% 937
2015
Q4 		$528K Buy
+3,806
New +$528K ﹤0.01% 917

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BNP Paribas Asset Management's BIO Position: Q2 2026 in Review

BNP Paribas Asset Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 14% in Q2 2026, selling an estimated $12.5K and leaving 277 shares worth $81.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1611.

BNP Paribas Asset Management first reported a position in BIO in Q4 2015 and has held it in 20 quarters since. The position peaked at $1.48M in Q1 2022. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • BNP Paribas Asset Management held 277 shares of Bio-Rad Laboratories Class A worth $81.3K as of Q2 2026.
  • BNP Paribas Asset Management sold 44 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $12.5K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #1611 holding.
  • BNP Paribas Asset Management first reported a position in Bio-Rad Laboratories Class A in Q4 2015 and has held it in 20 quarters since.
  • BNP Paribas Asset Management's Bio-Rad Laboratories Class A position peaked at $1.48M in Q1 2022.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.